Medscape

Molecular Methods in the Diagnosis and Management of Chronic Hepatitis B

The sensitivities of the aforementioned assays vary a lot. Direct sequencing-based assays have limited sensitivity, while assays based on PCR restriction fragment-length polymorphisms (RFLPs), ...
BioWorld

Precision Biosciences novel gene-editing approach may lead to a functional cure for HBV

The persistence of hepatitis B virus (HBV) covalently closed-circular DNA (cccDNA) and integration of HBV DNA into the hepatocytes lead to chronic HBV infection. Current therapies achieve long-term ...
TMCnet

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Con…

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Business Wire

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Business Wire

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

ELIMINATE-B Phase 1 dose finding study for chronic Hepatitis B executing on schedule with completion of first dose administration for cohort 1 (n=3 patients) PBGENE-HBV, the first LNP gene editing ...
BioWorld

MDL-001: oral polymerase inhibitor with dual HBV/HCV activity

Hepatitis B (HBV) and hepatitis C (HCV) remain major global public health challenges, with millions of individuals affected by chronic infection. While monoinfection with HBV or HCV can lead to ...